



Member Newsletter

2022 No. 009

Dear Member/Student,

Welcome to the latest World Trichology Society newsletter.

Upcoming Events

THE INAUGURAL WORLD CONGRESS OF TRICHOLOGY

SEPTEMBER 17-19, 2022

Location: Orlando Florida, USA

DoubleTree by Hilton™ at the Entrance to Universal Orlando

**For more information, please go to:
worldtrichologysummit.org**

Current Trichological and Health News

1. Mesotherapy With Dutasteride Appears To Be Safe, Effective For Treating Androgenetic Alopecia

Healio reports, “Mesotherapy with dutasteride was effective and associated with no serious side effects in a cohort of patients with androgenetic alopecia,” investigators concluded in a 541-patient study, the findings of which were published in the *Journal of Drugs in Dermatology*.

2. Dutasteride microinjections with oral minoxidil vs. oral minoxidil for androgenetic alopecia

A study published in the *Journal of the European Academy of Dermatology and Venereology* explored the effectiveness and safety of dutasteride intralesional microinjections (DIM) in combination with oral minoxidil compared with oral minoxidil monotherapy in men with androgenetic alopecia. In this retrospective single-center study, male patients were treated with oral minoxidil 1-5 mg daily alone or in combination with DIM. Observed side effects were related to oral minoxidil in both groups, and no sexual dysfunction was reported in any participant. Combination therapy of oral minoxidil with the intralesional dutasteride led to significantly greater improvement at the vertex compared with the outcomes of the oral minoxidil monotherapy. While more research is needed, the authors said that treatment efficacy and relief from risk of sexual dysfunction may provide an alternative therapeutic option for men.

3. Low-Level Light Therapy Cap May Be Safe, Convenient Treatment For Some Patients With Central Centrifugal Cicatricial Alopecia, Study Indicates

Medscape reports, “A low-level light therapy cap may be a safe, convenient treatment for some patients with central centrifugal cicatricial alopecia,” even “though the treatment effects from a small prospective trial appear to be subtle,” investigators concluded in findings presented in a poster at the Society for Investigative Dermatology 2022 Annual Meeting.

4. Study Says Many Patients Experienced Hair Loss Following COVID-19 Infection

Healio reported, “Many patients experienced significant hair loss following COVID-19 infection,” according to researchers who “conducted a retrospective study evaluating the prevalence of hair loss in patients who had recovered from COVID-19. Of 62 patients with hair loss, histological evaluations of hair samples from 48 had telogen effluvium, 12 showed evidence of androgenetic alopecia and two showed alopecia areata.” The findings were published in the Journal of Drugs and Dermatology.

5. Higher Doses Of Deuruxolitinib Tied To Improved Response Over 24 Weeks In Patients With AA.

Healio reports, “Higher doses of” CTP-543 (deuruxolitinib), “a novel Janus kinase inhibitor, were associated with improved response over 24 weeks in a cohort of patients with alopecia areata,” researchers concluded in a phase 2, 149-patient, “randomized, double-blind, placebo-controlled, sequential-design study.” The findings were published in the Journal of the American Academy of Dermatology.

6. People With Long COVID Experience Wider Set Of Symptoms Than Previously Thought

HealthDay reported, “People with long-haul COVID experience a wider set of symptoms than once thought...British researchers report” in an “analysis of electronic health records for 2.4 million U.K. residents.” The patterns of such “symptoms tended to be grouped mainly as respiratory or brain symptoms, alongside a third category representing a broader range of health problems, including hair loss and erectile dysfunction,” according to the results published in Nature Medicine. MedPage Today reported that “overall, 62 symptoms were significantly associated with a history of SARS-CoV-2 infection after 12 weeks, reported” researchers. The analysis also identified risk factors for long COVID, including “being part of an ethnic minority group, socioeconomic deprivation, smoking, obesity, and a wide range of comorbidities.”

7. Company To Seek FDA Approval For Experimental Hair Loss Drug After Success In Second Late-Stage Clinical Trial

BioPharma Dive reports, “Concert Pharmaceuticals, a small biotechnology company based in Lexington, Massachusetts, plans to seek Food and Drug Administration approval for its experimental hair loss drug after reporting success in the second of two late-stage clinical trials.” The article adds, “As in the first study, results from the second showed Concert’s treatment helped regrow hair to a significantly greater degree than a placebo, the company said in a Monday statement.” The company “expects to seek U.S. approval of the drug, dubbed CTP-543, in the first half of the year.”

8. Antioxidants May Function As Safe, Effective Treatment For Patients With Atopic Dermatitis, Especially When Supplemented With Oral Vitamin D And Topical B12, Systematic Review Suggests

HCPlive reported research indicates that “antioxidants could function as a safe and effective treatment for patients with atopic dermatitis, especially when supplemented with oral vitamin D and topical vitamin B12,” and “similar responses were recorded in pediatric patients with atopic dermatitis.” The findings of the 18-trial systematic review and meta-analysis encompassing “763 eligible patients with atopic dermatitis” were published online in the journal *Dermatologic Therapy*.

9. Patients With Alopecia Areata Prefer Shared Decision-Making Model With Dermatologists In Deciding Treatment, Survey Study Indicates

Healio reported, “Patients with alopecia areata preferred a shared decision-making model with their dermatologists in deciding treatment,” investigators concluded in a 1,074-patient survey study, the findings of which were published online in a brief report in *JAMA Dermatology*.

10. Dermatologists Increasingly Prescribing Low-Dose Minoxidil To Address Hair Loss

The New York Times reported “a growing group of dermatologists is offering low-dose minoxidil pills” to treat hair loss, but “the treatment remains relatively unknown to most patients and many [physicians].” The treatment “has not been approved by the Food and Drug Administration for this purpose and so is prescribed off-label.” Minoxidil’s “use as a hair-growth treatment was discovered by accident decades ago,” as high-dose pills “were being used to treat high blood pressure, but patients often noticed that the pills prompted hair growth all over their bodies.”

11. Characteristics Of Selective Serotonin Reuptake Inhibitor-Associated Alopecia

Dermatology Advisor reported, “The characteristics of alopecia associated with selective serotonin reuptake inhibitors (SSRIs) were outlined in study data published in *Psychiatry Research*.” According to the 38-study systematic review, “SSRI-associated alopecia most commonly affected the scalp and appeared a median of 8 weeks after initial drug exposure,” while “discontinuation of the SSRI led to recovery in more than half of episodes.”

12. Administration Of Minoxidil 5 Mg In Normotensive Patients With Androgenetic Alopecia May Produce Slight Reduction In Blood Pressure

Dermatology Advisor reports, “In patients with a history of postural hypotension who are receiving low-dose oral minoxidil (LDM) for androgenetic alopecia, the use of ambulatory blood pressure monitoring before the initial dose might be worth observing,” investigators concluded in a “before-after study...conducted in patients with androgenetic alopecia who were eligible for LDM treatment in real clinical practice.” The study revealed that “administration of minoxidil 5 mg in normotensive patients produced a slight reduction in blood pressure, in line with previous studies.” The findings (PDF) were published online in the *Journal of the American Academy of Dermatology*.

Journal Articles

For journal publications, click on the URL under the title of the topic you wish to see and it will open to a *free* abstract of the article. For obtaining the full article, just follow the relevant prompts on the site (*a payment may be required for the full article*).



1. **Recent modalities in treatment of Telogen Effluvium: Comparative study**

Fathia M. Khattab MD, Areeg Rady MSc., Shrook A. Khashaba MD
<https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.15720?>

2. **Intractable alopecia areata following the second dose of COVID-19 vaccination: Report of two cases**

Chieh-Hsun Chen, Yang-Yi Chen, Cheng-Che E. Lan
<https://onlinelibrary.wiley.com/doi/full/10.1111/dth.15689?>

3. **The role of lifestyle and nutrition in psoriasis: Current status of knowledge and interventions**

Maria L. Musumeci, Maria R. Nasca, Simona Boscaglia, Giuseppe Micali
<https://onlinelibrary.wiley.com/doi/full/10.1111/dth.15685?>

4. **Comparative study between topical methotrexate 1% gel and minoxidil 5% gel in the treatment of localized alopecia areata**

Dalia Mahmoud Toma, Rabie Bedir Atallah, Ramadan Mohamed Eldahshan
<https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.15696?>

5. **Latest Combination Therapies in Psoriasis**

Federico Diotallevi, Matteo Paolinelli, Giulia Radi, Annamaria Offidani
<https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.15759?>

1. **A prospective real world study evaluating serum levels of arginine and cysteine in females with chronic telogen effluvium: Do we really need blanket prescription with amino acid supplementation?**

Damini Arora, Pooja Arora, Parul Goyal, Purnima Paliwal, Kabir Sardana
<https://onlinelibrary.wiley.com/doi/abs/10.1111/ced.15333?>

2. **Anifrolumab for Treatment of Refractory Cutaneous Lupus Erythematosus**

Franklin R. Blum, Ashwath J. Sampath, Galen T. Foulke
<https://onlinelibrary.wiley.com/doi/abs/10.1111/ced.15335?>

3. **Does topical minodixil in concentrations higher than 5% provide additional clinical benefit?**

Mohamad Goldust, Shreya Singh, Anant Patil, Nika Kianfar, Anna Waskiel-Burnat, Lidia Rudnicka, Rodney Sinclair
<https://onlinelibrary.wiley.com/doi/abs/10.1111/ced.15338?>



1. **Alopecia and hyperpigmentation in a neonatal patient with lanosterol synthase gene deficiency and Spectrin alpha, non-erythrocytic 1 mutation**

Teresa L. Xiao BA, Adena E. Rosenblatt MD, PhD
<https://onlinelibrary.wiley.com/doi/full/10.1111/pde.15064?>

1. **Alopecia areata after CoronaVac vaccination**
Miguel Aristizabal MD, et al.
<https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.15184>

2. **Assessment of health-related quality of life in patients with FFA**
Aida Varghaei MD, et al.
<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15183>

3. **The potential role of fibroblast-derived multi-peptide factors in activation of growth factors and β -Catenin in hair follicle cells**
Jung-Min Shin, et al.
<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15188>

4. **Hair loss treatment and restoration: Online interest trends and video-based social media content**
Aditya K. Gupta MD, PhD, Deanna C. Hall PhD
<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15194>

5. **Characteristics of hair loss after COVID-19**
Torrey Czech MD, et al.
<https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.15218>

6. **Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in FFA**
Ghasem Rahmatpour Rokni MD, et al.
<https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.15232>

7. **A clinical evaluation of a permanent hair dye designed to reduce allergic contact dermatitis and hair damage**
Zoe Diana Draelos MD
<https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.15212>

8. Evaluation of efficacy of follicular unit extraction versus follicular unit extraction with platelet rich plasma in treatment of cicatricial alopecia

Ali Fouad Elariny MD, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15213?>

9. Protection of Hair Color With Pomegranate Peel Extract Loaded Liposomal Formulation

Sakine Tuncay Tanriverdi, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15254?>

10. Two Siblings with the Skin Fragility Woolly Hair Syndrome

Özge Aşkın, Defne Özkoca, Tuğba Kevser Uzunçakmak, Server Serdaroğlu

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15264?>

11. Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia

Lingling Jia, Jiachao Xiong, Rong Guo, Yufei Li, Hua Jiang

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15263?>

12. Isotretinoin-induced Hair disorders in the Era of COVID-19

Ayman Abdelmaksoud, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15214?>

13. Androgens and COVID-19

Kinnor Das MD, et al.

<https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.15090?>

14. Natural results of scalp micropigmentation: a review

Jae Hyun Park, Yeh Hong Ho, Kotchamol Manonukul

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15297?>

15. Inflammatory complications after hair transplantation

Sarra Saad MD, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.15244?>

1. **Circadian rhythms in psoriasis and the potential of chronotherapy in psoriasis management**

Andrea Luengas-Martinez, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.14649?>

2. **Trichothiodystrophy hair shafts display ultrastructural features**

Angeliki-Diotima Ioannidis, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/exd.14614?>

International Journal of Cosmetic Science



SOCIÉTÉ FRANÇAISE DE
COSMÉTOLOGIE



1. **Learning from hair moisture sorption and hysteresis**

S. Breakspear, P. Frueh, A. Neu, B. Noecker, C. Popescu, Q. Uellner

<https://onlinelibrary.wiley.com/doi/abs/10.1111/ics.12806?>

2. **Comparing hair tensile testing in the wet and the dry state**

Franz J. Wortmann, Jutta M. Quadflieg, Gabriele Wortmann

<https://onlinelibrary.wiley.com/doi/full/10.1111/ics.12796?>

3. **UV and visible light exposure to hair leads to widespread changes in the hair lipidome**

Alastair B. Ross, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/ics.12810?>

4. **New approach for hair keratin characterization**

M. Essendoubi, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/ics.12808?>

1. **Hair loss patterns in Hispanics with lichen planopilaris**

S. Chavez-Alvarez, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.18428?>

2. **Alopecia areata after COVID-19 infection and vaccination: a cross-sectional analysis**

Betty Nguyen, Antonella Tosti

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.18491?>



1. **Sebaceous gland atrophy in seborrheic dermatitis of the scalp**

Neha S. Nagrani MD, Lynne J. Goldberg MD

<https://onlinelibrary.wiley.com/doi/abs/10.1111/cup.14300?>

2. **The nit sheath: a rare clue for the diagnosis of louse infestation**

Zachary Theroux M.D., Eric Hossler M.D.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/cup.14301?>



1. **Tinea capitis in adult: role of trichoscopy in diagnosis, treatment, and follow-up**

Ankita Srivastava MD, Sanjiv Choudhary PhD

<https://onlinelibrary.wiley.com/doi/abs/10.1111/ijd.16392?>

CONTACT DERMATITIS

CUTANEOUS ALLERGY
ENVIRONMENTAL AND OCCUPATIONAL DERMATITIS

1. **Alopecia areata after severe allergic contact dermatitis to a permanent hair dye**

María E. Gatica-Ortega, et al.

<https://onlinelibrary.wiley.com/doi/abs/10.1111/cod.14201?>

**QUESTION FOR CTE® CREDIT (FOR MEMBERS ONLY): PLEASE
EMAIL ANSWER TO:
EDUCATION@WORLDTRICHOLOGYSOCIETY.ORG**

In Ioannidis' et al.'s research article regarding " Trichothiodystrophy hair shafts display ultrastructural features", what mineral was there a high paucity of?

©2022 World Trichology Society
www.WorldTrichologySociety.org
Email: info@WorldTrichologySociety.org
T: 1-718-698-4700